Immune checkpoint inhibitors (ICIs) show high-therapeutic efficacy against MSI-high/dMMR/PD-L1-positive tumor cells by inhibiting the binding between PD-1 and PD-L1, preventing immune cell suppression [5]. The gene discussed is CD274; the disease is neoplasm.